China
The iceberg beneath the surface – why China's clinical data is being questioned
In the fall of 2016, the curtain was drawn on one of the biggest scandals in medical history: more than 80 percent of China's clinical study data...
How European companies can succeed in the Chinese deal market
China is becoming an increasingly important player in the...
China as a key global player – insights from BioStock's expert panel
Are Nordic companies ready to benefit from...
M&A fever with over 280 deals in six months
The biopharma sector has had an explosive start to 2025....
Lobbying battle in the White House over Chinese medicines
The Trump administration is considering measures to reduce America's dependence on...
Semaglutide patent expiration opens the door to Chinese generics
Semaglutide, known as Ozempic for diabetes and Wegovy...
Summit and Akeso plunge into ambiguous data
The candidate who would beat Keytruda on the fingers meets...
BioNTech's HER2 ADC outperforms Roche's Kadcyla in Phase III study
BioNTech, in collaboration with Duality Biologics, has achieved...
Asia leads in bispecific ADCs
Bispecific antibody drug conjugates represent a new and promising development...
Big pharma lost 5,7 percent in market value
Big pharma is, as is well known, grappling with challenges to...
Novo Nordisk shows its forefoot in clinical practice
The battle over the obesity market is constantly intensifying and the attacks are intensifying...
Global giants make record investments in Chinese innovations
Amidst economic challenges and looming patent expirations,...